[1]劉申穎,施彥卿,梅鵬飛,等.超聲引導下經皮無水乙醇注射聯合射頻消融治療中晚期肝癌的效果[J].醫學信息,2019,(22):87-90.[doi:10.3969/j.issn.1006-1959.2019.22.026]
 LIU Shen-ying,SHI Yan-qing,MEI Peng-fei,et al.Ultrasound-guided Percutaneous Ethanol Injection Combined with Radiofrequency Ablation for Advanced Hepatocellular Carcinoma[J].Medical Information,2019,(22):87-90.[doi:10.3969/j.issn.1006-1959.2019.22.026]
點擊復制

超聲引導下經皮無水乙醇注射聯合射頻消融治療中晚期肝癌的效果()
分享到:

醫學信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期數:
2019年22期
頁碼:
87-90
欄目:
論著
出版日期:
2019-11-15

文章信息/Info

Title:
Ultrasound-guided Percutaneous Ethanol Injection Combined with Radiofrequency Ablation for Advanced Hepatocellular Carcinoma
文章編號:
1006-1959(2019)22-0087-04
作者:
劉申穎12施彥卿12梅鵬飛12李志英12雷 霞 12
(1.九江學院附屬醫院消化內科,江西 九江 332000;2.九江學院附屬消化內科研究所,江西 九江 332000)
Author(s):
LIU Shen-ying12SHI Yan-qing12MEI Peng-fei12LI Zhi-ying12LEI Xia12
(1.Department of Gastroenterology,Affiliated Hospital of Jiujiang University,Jiujiang 332000,Jiangxi,China;2.Institute of Gastroenterology,Jiujiang University,Jiujiang 332000,Jiangxi,China)
關鍵詞:
經皮無水乙醇注射經皮射頻消融術肝癌存活率谷丙轉氨酶總膽紅素
Keywords:
Percutaneous ethanol injectionPercutaneous radiofrequency ablationLiver cancerSurvival rateAlanine aminotransferaseTotal bilirubin
分類號:
R735.7
DOI:
10.3969/j.issn.1006-1959.2019.22.026
文獻標志碼:
A
摘要:
目的 觀察超聲引導下經皮無水乙醇注射(PEI)聯合經皮射頻消融(PRFA)治療中晚期肝癌(HCC)的臨床有效性和安全性。方法 選擇2010年1月~2016年12在我院診斷為Ⅲ~Ⅳ期HCC的患者85例,根據數字隨機法分為A(28例)、B(29例)、C(28例)三組,A組患者用PEI開始治療,1~2周后予PRFA治療;B組患者先行PRFA治療,1~2周后行PEI治療;C組患者同時接受PEI和PRFA治療。隨訪6個月~3年,比較三組患者生存率、腫瘤消融壞死體積、消融后體積、完全消融率、無水乙醇用量、射頻能量及肝功能損害指數(谷丙轉氨酶和總膽紅素水平)。結果 A組患者生存率高于B組和C組,差異有統計學意義(P<0.05);B組腫瘤消融壞死體積大于A組和C組,差異有統計學意義(P<0.05);B組消融后體積小于A組和C組,差異有統計學意義(P<0.05);B組完全消融率為82.76%,高于A組的71.43%和C組的64.29%,差異有統計學意義(P<0.05);三組患者無水乙醇用量、射頻能量能比較,差異無統計學意義(P>0.05);三組治療前后谷丙轉氨酶和總膽紅素水平比較,差異無統計學意義(P>0.05)。結論 PEI和PRFA治療中晚期肝癌安全且有效的,其中以PEI聯合PRFA序貫治療效果為佳。
Abstract:
Objective To observe the clinical efficacy and safety of ultrasound-guided percutaneous ethanol injection (PEI) combined with percutaneous radiofrequency ablation (PRFA) in the treatment of advanced liver cancer (HCC). Methods 85 patients with stage III~IV HCC diagnosed in our hospital from January 2010 to December 2016 were enrolled. According to the numerical randomization method, they were divided into three groups: A (28 cases), B (29 cases) and C (28 cases). Patients in group A were treated with PEI and treated with PRFA 1 to 2 weeks later. Group B patients were treated with PRFA first, and PEI was treated 1 to 2 weeks later. Group C patients were treated with PEI and PRFA. After 6 months to 3 years of follow-up, the survival rate, tumor ablation necrosis volume, ablation volume, complete ablation rate, absolute ethanol dosage, radiofrequency energy and liver function damage index (alanine aminotransferase and total bilirubin levels) were compared between the three groups. Results The survival rate of patients in group A was higher than that in group B and C,the difference was statistically significant (P<0.05). The tumor ablation necrosis volume in group B was greater than that in group A and group C, the difference was statistically significant (P<0.05). The volume of group B after ablation was smaller than group A and group C,the difference was statistically significant(P<0.05); the complete ablation rate of group B was 82.76%, higher than 71.43% in group A and 64.29% in group C, the difference was statistically significant (P<0.05); the amount of absolute ethanol in the three groups,there was no significant difference in radiofrequency energy (P>0.05). There was no significant difference in the levels of alanine aminotransferase and total bilirubin between the three groups before and after treatment (P>0.05). Conclusion PEI and PRFA are safe and effective in the treatment of advanced liver cancer. The sequential treatment with PEI combined with PRFA is better.

參考文獻/References:

[1]Ozakyol A.Global Epidemiology of Hepatocellular Carcinoma (HCC Epidemiology)[J].Journal of Gastrointestinal Cancer,2017,48(3):238-240. [2]Ghouri YA,Mian I,Rowe JH.Review of hepatocellular carcinoma: Epidemiology, etiology, and carcinogenesis[J].Journal of Carcinogenesis,2017,16(1):1. [3]Hou W,Zhu X.Extra vascular interventional treatment of liver cancer, present and future[J].Drug Discoveries & Therapeutics,2015,9(5):335-341. [4]Song P,Wang M,Ning WU,et al.Interventional therapy for primary hepatic carcinoma associated with IVC- RA tumor thrombus:initial experience in 17 cases[J].Journal of Interventional Radiology,2017,26(2):129-132.. [5]Xu L T,Zhou ZH,Lin JH,et al.Clinical study of transarterial chemoembolization combined with 3-dimensional conformal radiotherapy for hepatocellular carcinoma[J].European Journal of Surgical Oncology,2011,37(3):250-251. [6]Nouso K,Kariyama K,Nakamura S,et al.Application of Radiofrequency Ablation for the Treatment of Intermediate-Stage Hepatocellular Carcinoma[J].Journal of Gastroenterology & Hepatology,2017,32(3):695. [7]Chen S,Peng Z,Lin M,et al.Combined percutaneous radiofrequency ablation and ethanol injection versus hepatic resection for 2.1~5.0 cm solitary hepatocellular carcinoma: a retrospective comparative multicentre study[J].European Radiology,2018,28(9):3651-3660. [8]Peng C,Zhang Z,Liu J,et al.Efficacy and safety of ultrasound-guided radiofrequency ablation of hyperplastic parathyroid gland for secondary hyperparathyroidism associated with chronic kidney disease[J].Head & Neck,2017,39(3):564. [9]Wu J,Chen P,Xie YG,et al.Comparison of the effectiveness and safety of ultrasound- and CT-guided percutaneous radiofrequency ablation of non-operation hepatocellular carcinoma[J].Pathology & Oncology Research,2015,21(3):637-642. [10]Zhang W,Luo E,Gan J,et al.Long-term survival of hepatocellular carcinoma after percutaneous radiofrequency ablation guided by ultrasound[J].World Journal of Surgical Oncology,2017,15(1):122. [11]Clark TW.Chemical ablation of liver cancer[J].Techniques in Vascular & Interventional Radiology,2007,10(1):58-63. [12]Shiina S.Percutaneous ethanol injection therapy for hepatocellular-carcinoma (review)[J].International Journal of Oncology,1993,2(4):669. [13]Livraghi T,Giorgio A,Marin G,et al.Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection[J].Radiology,1995,197(1):101-108. [14]Rossi S.Percutaneous Radiofrequency Interstitial Thermal Ablation in the treatment of small hepatocellular carcinoma[J].Cancer J Sci Am,1995,1(1):73-81. [15]Wahl DR,Stenmark MH,Tao Y,et al.Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma[J].Journal of Clinical Oncology,2015,34(5):452. [16]Kai L,Jia L,Zhi-Gang W,et al.Ultrasonic guided percutaneous ethanol injection with or without combined radiofrequency ablation for hepatocellular carcinomas[J].Indian Journal of Cancer,2015,52 Suppl(6):E102. [17]Rehman J,Landman J,Lee D,et al.Needle-Based Ablation of Renal Parenchyma Using Microwave, Cryoablation, Impedance- and Temperature-Based Monopolar and Bipolar Radiofrequency, and Liquid and Gel Chemoablation: Laboratory Studies and Review of the Literature[J].Journal of Endourology,2004,18(1):83-104. [18]Ogasawara S,Chiba T,Ooka Y,et al.Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib[J].Investigational New Drugs,2016,34(2):255-260.

更新日期/Last Update: 2019-11-15
中国足彩网竞彩